**ACURATE neo2 vs. Evolut PRO/PRO+**

Results from NEOPRO-2: A retrospective registry of 2175 TAVR patients with either ACURATE neo2 (N=763) or Evolut PRO/PRO+ (N=1421).

**In-hospital outcomes**

- **High technical success**
  - NEO2: 93.1% vs PRO: 94.1% ($p=NS$)
  - **Comparable pre-discharge valve performance**
    - NEO2: 96.0% vs PRO: 94.1% ($p=NS$)

**30-day device success and early safety**

- **Device success**
  - NEO2: 84% vs PRO: 79%
  - **Early safety**
    - NEO2: 71% vs PRO: 79%

**30-day outcomes**

- **All-cause death**: 2.5% (NEO2 vs PRO: $p=NS$)
- **Stroke**: 2.9%

**neo2: Lower rates of new PPI**

- **Entire population**: NEO2: 7.7% vs PRO: 15.6% ($p<0.001$)
- **PS-matched analysis (n=452)**: NEO2: 6.7% vs PRO: 16.7% ($p<0.001$)

**Paravalvular AR (%)**

- NEO2: 59.0% vs PRO: 59.3%
  - **Paravalvular AR**
    - Minor
    - Moderate
    - Severe

*Analysis performed in the overall cohort as well as propensity-score (PS) matched cohorts*

When compared to Evolut PRO/PRO+, **ACURATE neo2 demonstrated**:

- **Higher rates of early safety** - driven by significantly lower rates of PPI
- **Lower rates of moderate-severe PAR**, even in heavily calcified aortic valves

---


**CAUTION:** In Europe, ACURATE neo and neo2 Aortic Valve Systems are CE-marked. In the USA, ACURATE neo2 is an investigational device and restricted under federal law to investigational use only. Not available for sale.